Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Announce Earnings of -$0.76 Per Share

Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report ($0.76) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($0.80). Lexicon Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 375%. The company is scheduled to issue its next quarterly earnings results on Wednesday, March 11th.

On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.83 per share for the current financial year, with EPS estimates ranging from $0.78 to $0.87. For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.55). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The business’s revenue was up 4124.5% compared to the same quarter last year.

A number of equities research analysts recently weighed in on the company. Gabelli upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Wednesday, September 11th. BidaskClub cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. G.Research upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Wedbush restated a “buy” rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday. Finally, Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.45.

In other Lexicon Pharmaceuticals news, Director Christopher J. Sobecki purchased 25,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was bought at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the purchase, the director now owns 112,493 shares in the company, valued at approximately $286,857.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher J. Sobecki purchased 99,249 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was acquired at an average price of $2.41 per share, with a total value of $239,190.09. Following the completion of the purchase, the director now owns 13,645 shares of the company’s stock, valued at approximately $32,884.45. The disclosure for this purchase can be found here. Insiders have purchased a total of 178,749 shares of company stock valued at $474,560 over the last 90 days. 6.40% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in LXRX. Quantitative Systematic Strategies LLC raised its stake in Lexicon Pharmaceuticals by 67.2% in the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 8,302 shares during the last quarter. Wedbush Securities Inc. raised its stake in Lexicon Pharmaceuticals by 33.0% in the second quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock valued at $1,222,000 after buying an additional 48,182 shares during the last quarter. Swiss National Bank raised its stake in Lexicon Pharmaceuticals by 18.3% in the second quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 13,700 shares during the last quarter. GSA Capital Partners LLP raised its stake in Lexicon Pharmaceuticals by 217.5% in the second quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock valued at $548,000 after buying an additional 59,685 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Lexicon Pharmaceuticals in the second quarter valued at about $92,000. Institutional investors own 96.27% of the company’s stock.

Shares of LXRX traded up $0.47 during midday trading on Wednesday, reaching $3.77. 1,995,599 shares of the stock were exchanged, compared to its average volume of 1,297,426. Lexicon Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $8.39. The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42. The company’s 50 day moving average is $3.63 and its two-hundred day moving average is $3.88. The company has a market capitalization of $400.65 million, a P/E ratio of -3.31 and a beta of 1.00.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: What is quantitative easing?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.